Trials / Completed
CompletedNCT01493180
Exploratory Study of OPC-12759 Ophthalmic Suspension
Exploratory Study of OPC-12759 Ophthalmic Suspension in Patients With Keratoconjunctiva Epithelial Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of OPC-12759 ophthalmic suspension for patients with keratoconjunctival epithelial disorder compared with sodium hyaluronate. Also, safety of OPC-12759 is to be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-12759 ophthalmic suspension | OPC-12759 ophthalmic suspension 2% |
| DRUG | Sodium hyaluronate ophthalmic solution | Sodium hyaluronate ophthalmic solution 0.1% |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2012-11-01
- Completion
- 2012-12-01
- First posted
- 2011-12-15
- Last updated
- 2015-03-10
- Results posted
- 2014-03-03
Locations
10 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01493180. Inclusion in this directory is not an endorsement.